Related Experiment Video

Updated: Aug 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aldosterone Receptor Blockers in the Treatment of Heart Failure

Anita Deswal1, David Yao

  • 1Michael E. DeBakey VA Medical Center (152), Section of Cardiology, 2002 Holcombe Boulevard, Houston, TX 77030, USA. adeswal@bcm.tmc.edu

Current Treatment Options in Cardiovascular Medicine
|June 24, 2004
PubMed

Insights

Aldosterone receptor blockers improve outcomes in severe heart failure by blocking harmful effects, but require careful monitoring of potassium levels and kidney function to prevent serious side effects like hyperkalemia.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Heart failure involves neurohormonal activation, notably the renin-angiotensin-aldosterone system.
  • Elevated aldosterone in heart failure persists despite ACE inhibitors or ARBs due to angiotensin-independent production.
  • Aldosterone contributes to myocardial and vascular fibrosis and adverse cardiac remodeling.

Purpose of the Study:

  • To review the role of aldosterone receptor blockers in managing heart failure.
  • To highlight clinical trial evidence supporting their use in specific heart failure populations.
  • To emphasize monitoring requirements and contraindications for aldosterone receptor blockers.

Main Methods:

  • Analysis of clinical trial data (e.g., RALES, EPHESUS) on aldosterone receptor blockers.
  • Review of aldosterone's pathophysiological effects in heart failure.
  • Guidelines for safe initiation and management of aldosterone receptor blockers.

Main Results:

  • Low-dose aldosterone receptor blockers improve morbidity and mortality in severe chronic heart failure and post-myocardial infarction heart failure.
  • These agents are recommended as add-on therapy to standard treatments like ACE inhibitors/ARBs and beta-blockers.
  • Effective management requires close serum potassium monitoring and dose adjustment.

Conclusions:

  • Aldosterone receptor blockers are valuable in managing specific heart failure patients.
  • Vigilant monitoring for hyperkalemia and renal function is crucial for safe use.
  • Adherence to recommended dosing and monitoring protocols is essential.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...